JP2022551270A - ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体 - Google Patents

ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体 Download PDF

Info

Publication number
JP2022551270A
JP2022551270A JP2022520475A JP2022520475A JP2022551270A JP 2022551270 A JP2022551270 A JP 2022551270A JP 2022520475 A JP2022520475 A JP 2022520475A JP 2022520475 A JP2022520475 A JP 2022520475A JP 2022551270 A JP2022551270 A JP 2022551270A
Authority
JP
Japan
Prior art keywords
compound
och
independently
ocf
ch2ch3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022520475A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551270A5 (cg-RX-API-DMAC10.html
Inventor
デニス キーフ
グオズー ゼン
パヴェルス アルセンジャンス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Biotherapeutics Inc
Original Assignee
Stealth Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Biotherapeutics Inc filed Critical Stealth Biotherapeutics Inc
Publication of JP2022551270A publication Critical patent/JP2022551270A/ja
Publication of JP2022551270A5 publication Critical patent/JP2022551270A5/ja
Priority to JP2025113088A priority Critical patent/JP2025164962A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/18—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring
    • C07C39/19—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/835—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups having unsaturation outside an aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
JP2022520475A 2019-10-04 2020-10-02 ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体 Pending JP2022551270A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025113088A JP2025164962A (ja) 2019-10-04 2025-07-03 ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962911069P 2019-10-04 2019-10-04
US62/911,069 2019-10-04
US202062991525P 2020-03-18 2020-03-18
US62/991,525 2020-03-18
PCT/US2020/054107 WO2021067836A1 (en) 2019-10-04 2020-10-02 Chinone-, hydrochinome- and naphthochinone-analogues of vatiquione for treatment of mitochondrial disorder diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025113088A Division JP2025164962A (ja) 2019-10-04 2025-07-03 ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体

Publications (2)

Publication Number Publication Date
JP2022551270A true JP2022551270A (ja) 2022-12-08
JP2022551270A5 JP2022551270A5 (cg-RX-API-DMAC10.html) 2024-03-28

Family

ID=72964859

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022520475A Pending JP2022551270A (ja) 2019-10-04 2020-10-02 ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体
JP2025113088A Pending JP2025164962A (ja) 2019-10-04 2025-07-03 ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025113088A Pending JP2025164962A (ja) 2019-10-04 2025-07-03 ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体

Country Status (9)

Country Link
US (4) US11584728B2 (cg-RX-API-DMAC10.html)
EP (1) EP4038076A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022551270A (cg-RX-API-DMAC10.html)
KR (1) KR20220078644A (cg-RX-API-DMAC10.html)
CN (2) CN114746430B (cg-RX-API-DMAC10.html)
AU (2) AU2020358970C1 (cg-RX-API-DMAC10.html)
CA (1) CA3156499A1 (cg-RX-API-DMAC10.html)
IL (2) IL291898B1 (cg-RX-API-DMAC10.html)
WO (1) WO2021067836A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025164962A (ja) * 2019-10-04 2025-10-31 ステルス バイオセラピューティクス インコーポレイテッド ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022291142A1 (en) * 2021-06-10 2023-12-21 Stealth Biotherapeutics Inc. Compounds, compositions and methods for the prevention and/or treatment of various mitochondrial diseases or disorders, including friedreich's ataxia
US11541116B1 (en) 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo
AU2024300048A1 (en) * 2023-07-21 2026-01-22 Stealth Biotherapeutics Inc. Methods, compositions and uses related to the treatment and prevention of leigh's syndrome
AU2024377199A1 (en) * 2023-11-09 2026-05-21 Stealth Biotherapeutics Inc. Cyclo-hexa-2,5-diene-1,4-diones for use in the treatment of cardiomyopathy
WO2025231245A1 (en) * 2024-05-02 2025-11-06 Stealth Biotherapeutics Inc. Use of substituted 1,4 benzoquinones to treat alpha-synucleinopathies
WO2026020091A1 (en) * 2024-07-19 2026-01-22 Stealth Biotherapeutics Inc. Methods, compounds, compositions, formulations and uses for addressing mitochondrial disease resulting from nuclear dna mutations
WO2026050137A1 (en) * 2024-08-26 2026-03-05 Stealth Biotherapeutics Inc. A combination therapy for the treatment of friedreich's ataxia

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542389A (ja) * 2005-06-01 2008-11-27 エジソン ファーマシューティカルズ, インコーポレイテッド ミトコンドリア病および他の状態の治療、およびエネルギーバイオマーカーの調節のための酸化還元活性治療薬
JP2009527567A (ja) * 2006-02-22 2009-07-30 エジソン ファーマシューティカルズ, インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
WO2012022467A2 (en) * 2010-08-16 2012-02-23 Santhera Pharmaceuticals (Schweiz) Ag Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function
WO2012068552A1 (en) * 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control
JP2016041772A (ja) * 2010-08-06 2016-03-31 エジソン ファーマシューティカルズ, インコーポレイテッド ナフトキノンによるミトコンドリア病の処置
JP2016515526A (ja) * 2013-03-15 2016-05-30 エジソン ファーマシューティカルズ, インコーポレイテッド 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体
WO2017087795A1 (en) * 2015-11-19 2017-05-26 Concert Pharmaceuticals, Inc. Deuterated epi-743
WO2018191732A1 (en) * 2017-04-14 2018-10-18 Bioelectron Technology Corporation Methods and compositions for treatment of inflammation and oxidative stress
JP2019504018A (ja) * 2015-12-17 2019-02-14 バイオエレクトロン テクノロジー コーポレイション 酸化ストレス障害を処置するためのフルオロアルキル、フルオロアルコキシ、フェノキシ、ヘテロアリールオキシ、アルコキシ、およびアミノ1,4−ベンゾキノン誘導体

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
CA2272971C (en) 1998-10-29 2008-01-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
JP2009508867A (ja) 2005-09-15 2009-03-05 エジソン ファーマシューティカルズ, インコーポレイテッド ミトコンドリア病および関連した様態の治療ならびにエネルギーバイオマーカーの調節のための酸化還元活性治療剤のテイル改変体
EP2332534B1 (en) * 2006-02-22 2018-11-14 Bioelectron Technology Corporation Phenol and benzoquinone derivatives for use in the treatment of mitochondrial diseases and modulation of energy biomarkers
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
EP2303824B1 (en) 2008-06-25 2015-03-25 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
WO2010051277A1 (en) 2008-10-28 2010-05-06 Edison Pharmaceuticals, Inc. Process for the production of alpha-tocotrienol and derivatives
EP2246048A1 (en) 2009-04-30 2010-11-03 Santhera Pharmaceuticals (Schweiz) AG Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis
NO2470168T3 (cg-RX-API-DMAC10.html) 2009-08-26 2018-06-30
HRP20161407T1 (hr) 2010-08-16 2016-12-02 Santhera Pharmaceuticals (Schweiz) Ag Derivati benzokinona za liječenje mitohondrijskih bolesti oka
WO2012170773A1 (en) 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
KR102137450B1 (ko) * 2012-07-12 2020-07-27 콘드리온 아이피 비.브이. 미토콘드리아 질환을 치료하기 위한 크로마닐 유도체
CA2883879A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
JP6367211B2 (ja) 2012-11-16 2018-08-01 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ リソソーム蓄積症の改善物質としてのトコフェロール誘導体およびトコフェリルキノン誘導体
WO2015183963A2 (en) 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including redox-active parabenzoquinones and uses thereof
CA3011293A1 (en) 2016-01-12 2017-07-20 Ptc Therapeutics, Inc. Tocopherol and tocotrienol quinone derivatives for increasing thiosulfate levels or decreasing hydrogen sulfide levels
JP7266304B2 (ja) 2017-04-21 2023-04-28 ユニヴァーシティー オブ タスマニア 治療化合物および方法
IL305687B2 (en) 2017-12-15 2024-12-01 Stealth Biotherapeutics Inc Mitochondria-targeting peptides
IL291898B1 (en) * 2019-10-04 2026-06-01 Stealth Biotherapeutics Inc Quinone-, hydroquinone-, and naphthoquinone- analogs of quinone for the treatment of mitochondrial disorders

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542389A (ja) * 2005-06-01 2008-11-27 エジソン ファーマシューティカルズ, インコーポレイテッド ミトコンドリア病および他の状態の治療、およびエネルギーバイオマーカーの調節のための酸化還元活性治療薬
JP2009527567A (ja) * 2006-02-22 2009-07-30 エジソン ファーマシューティカルズ, インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
JP2016041772A (ja) * 2010-08-06 2016-03-31 エジソン ファーマシューティカルズ, インコーポレイテッド ナフトキノンによるミトコンドリア病の処置
WO2012022467A2 (en) * 2010-08-16 2012-02-23 Santhera Pharmaceuticals (Schweiz) Ag Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function
WO2012068552A1 (en) * 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control
JP2016515526A (ja) * 2013-03-15 2016-05-30 エジソン ファーマシューティカルズ, インコーポレイテッド 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体
WO2017087795A1 (en) * 2015-11-19 2017-05-26 Concert Pharmaceuticals, Inc. Deuterated epi-743
JP2019504018A (ja) * 2015-12-17 2019-02-14 バイオエレクトロン テクノロジー コーポレイション 酸化ストレス障害を処置するためのフルオロアルキル、フルオロアルコキシ、フェノキシ、ヘテロアリールオキシ、アルコキシ、およびアミノ1,4−ベンゾキノン誘導体
WO2018191732A1 (en) * 2017-04-14 2018-10-18 Bioelectron Technology Corporation Methods and compositions for treatment of inflammation and oxidative stress

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. Vol.20(3), JPN6024029503, 2010, pages 1063 - 1064, ISSN: 0005378595 *
EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, vol. 5, JPN6024029504, 1999, pages 1075 - 1084, ISSN: 0005378594 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025164962A (ja) * 2019-10-04 2025-10-31 ステルス バイオセラピューティクス インコーポレイテッド ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体

Also Published As

Publication number Publication date
WO2021067836A1 (en) 2021-04-08
AU2020358970B2 (en) 2026-02-05
US11584728B2 (en) 2023-02-21
KR20220078644A (ko) 2022-06-10
AU2020358970C1 (en) 2026-08-06
US20210206736A1 (en) 2021-07-08
IL328635A (en) 2026-07-01
CA3156499A1 (en) 2021-04-08
CN114746430A (zh) 2022-07-12
CN121949079A (zh) 2026-05-01
JP2025164962A (ja) 2025-10-31
US20240368098A1 (en) 2024-11-07
IL291898B1 (en) 2026-06-01
CN114746430B (zh) 2026-01-30
US20230303506A1 (en) 2023-09-28
EP4038076A1 (en) 2022-08-10
AU2026203365A1 (en) 2026-07-23
US12049455B2 (en) 2024-07-30
US20240400529A1 (en) 2024-12-05
IL291898A (en) 2022-06-01
AU2020358970A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
AU2020358970B2 (en) Chinone-, hydrochinome- and naphthochinone-analogues of vatiquione for treatment of mitochondrial disorder diseases
TWI689490B (zh) 用於治療纖維化之經取代之芳族化合物及相關方法
EP3983384B1 (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
JP6107650B2 (ja) テトラヒドロカルボリン誘導体
US12037350B2 (en) Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia
CA3222132A1 (en) Compounds, compositions and methods for the prevention and/or treatment of various mitochondrial diseases or disorders, including friedreich's ataxia
WO2017124949A1 (zh) 二氢黄酮衍生物、其制备方法和用途
HK40088188A (en) Compositions and methods for preventing and/or treating mitochondrial diseases, including friedreich's ataxia
HK40088188B (en) Compositions and methods for preventing and/or treating mitochondrial diseases, including friedreich's ataxia
CN118382435A (zh) 12/15-脂氧合酶抑制剂
CN114920697A (zh) 杂环基取代的茚满丙酰胺类化合物及其应用
CN120282779A (zh) 4(rs)-4-f4-神经前列腺素衍生物(4-f4t-neurop)及其在治疗呼吸机导致的膈肌功能障碍和其他疾病中的用途
WO2005005433A1 (ja) 高カルシウム血症および骨疾患治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240314

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250703